Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hudefi, Fayz
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Active, not recruiting	2	350	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	12/24	05/25
OUTLAST, NCT05034874: Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200	Terminated	2	61	US	IXT-m200, Placebo	InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA)	Methamphetamine-dependence, Methamphetamine Abuse	09/23	11/23